MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Progressive supranuclear palsy(PSP)"

  • 2019 International Congress

    Baseline analysis of PROSPECT-M-UK: a longitudinal study of PSP, CBS and MSA

    E. Jabbari, J. Woodside, V. Chelban, A. Costantini, N. Holland, N. Leigh, D. Burn, N. Pavese, A. Gerhard, C. Kobylecki, M. Hu, A. Church, J. Rohrer, H. Houlden, J. Rowe, H. Morris (London, United Kingdom)

    Objective: To complete the baseline analysis of clinical data from the PROSPECT-M-UK study and to assess the impact of applying current MDS PSP diagnostic criteria…
  • 2019 International Congress

    Validation of the Movement Disorder Society criteria for the diagnosis of 4R-tauopathies

    G. Respondek, MJ. Grimm, I. Piot, T. Arzberger, Y. Compta, E. Englund, LW. Ferguson, E. Gelpi, A. Giese, S. Roeber, DJ. Irwin, WG. Meissner, C. Nilsson, A. Pantelyat, A. Rajput, JB. Rowe, JC. van Swieten, C. Troakes, GU. Höglinger (London, United Kingdom)

    Objective: To validate the accuracy of the newly proposed Movement Disorder Society diagnostic criteria for progressive supranuclear palsy (MDS-PSP criteria, Höglinger et al., 2017) to…
  • 2019 International Congress

    Molecular correlates of survival and clinical severity in Progressive Supranuclear Palsy

    M. Malpetti, L. Passamonti, T. Rittman, P. Vázquez Rodríguez, W R. Bevan-Jones, F I. Aigbirhio, J T. O'Brien, J B. Rowe (Cambridge, United Kingdom)

    Objective: To test how regional tau pathology and neuroinflammation are associated with clinical severity and survival in progressive supranuclear palsy (PSP). Background: The abnormal aggregation…
  • 2019 International Congress

    Validation of the diagnostic criteria for progressive supranuclear palsy in pathologically confirmed patients

    I. Aiba, Y. Saito, Y. Yokokawa, T. Katayama, M. Kenjo, R. Hashimoto, S. Sakakibara, M. Sato, H. Nakatsuji, A. Inukai, Y. Iwasaki, M. Mimuro, A. Akagi, M. Yoshida (Nagoya, Japan)

    Objective: To assess the sensitivity and specificity of the diagnostic criteria for progressive supranuclear palsy (PSP). Background: The International Parkinson and Movement Disorder Society criteria…
  • 2019 International Congress

    Concomitant brain pathologies have no major impact on clinical milestones in progressive supranuclear palsy

    M. Jecmenica-Lukic, C. Kurz, G. Respondek, O. Grau-Rivera, Y. Compta, E. Gelpi, C. Troakes, J. van Swieten, A. Giese, S. Roeber, T. Arzberger, G. Höglinger (Munich, Germany)

    Objective: To analyze the frequency and severity of co-pathologies in PSP patients and their relevance for the clinical presentation and progression in PSP. Background: The phenotypic…
  • 2019 International Congress

    Abnormal metabolic brain network in multiple system atrophy and progressive supranuclear palsy: a replication on a new European cohort

    T. Rus, E. Rebec, P. Tomše, A. Studen, M. Grmek, C. Tang, D. Eidelberg, M. Trošt (Ljubljana, Slovenia)

    Objective: To identify characteristic metabolic brain patterns specific for multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) in a new cohort of patients and…
  • 2019 International Congress

    Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?

    G. Marti-Andres, M. Riverol-Fernandez, R. Valentí-Azcárate, M. Fernández-Matarrubia, E. Prieto-Azcárate, J. Arbizu-Azcarate, MR. Luquin-Piudo (Pamplona, Spain)

    Objective: To assess if there are differential metabolic brain patterns among Progressive Supranuclear Palsy(PSP) clinical variants and between them and Parkinson’s disease patients (PD). Background:…
  • 2019 International Congress

    Application of the Movement Disorders Society Criteria for diagnosis of Progressive Supranuclear Palsy

    F. Ali, H. Botha, E. Ahlskog, J. Bower, A. Hassan, D. Dickson, J. Whitwell, K. Josephs (Rochester, MN, USA)

    Objective: Analyze the sensitivity, specificity of the Movement Disorders Society (MDS) criteria for progressive supranuclear palsy (PSP) and apply the multiple allocation extinction (MAX) rules…
  • 2019 International Congress

    Cerebellar involvement in progressive supranuclear palsy and corticobasal degeneration

    S. Jo, KW. Park, N. Choi, CS. Lee, MS. Kim (Seoul, Republic of Korea)

    Objective: To investigate cerebellar involvement in vivo in patients with corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) using [18F]FDG PET. Background: Cerebellar ataxia is…
  • 2019 International Congress

    [18F]THK-5351 PET Imaging in Progressive Supranuclear Palsy Concomitant with Cerebellar Ataxia in Early-stage: Clinicopathological Observations

    Y. Saitoh, K. Komatsu, E. Imabayashi, A. Moriya, H. Matsuda, Y. Saito, Y. Takahashi (Tokyo, Japan)

    Objective: To describe two cases of progressive supranuclear palsy (PSP) concomitant with cerebellar ataxia in early stage who underwent [18F]THK-5351 PET imaging and to investigate…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 42
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley